Ramesh Jayaraman

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

Inflammation and cancer: advances and new agents

Cell cycle proteins as promising targets in cancer therapy

Interleukin-6 signaling pathway in targeted therapy for cancer

New treatment for acute myelogenous leukemia

Macrophages in immunoregulation and therapeutics

The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer

Inflammation and tumor progression: signaling pathways and targeted intervention

The JAK/STAT signaling pathway: from bench to clinic

Targeting apoptosis in cancer therapy

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Emerging drug profile: cyclin-dependent kinase inhibitors

Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer

Pacritinib: a new agent for the management of myelofibrosis?

Investigational Janus kinase inhibitors

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

The promise of Janus kinase inhibitors in the treatment of hematological malignancies

Cancer-related inflammation and treatment effectiveness

The history and future of targeting cyclin-dependent kinases in cancer therapy

Molecular pathogenesis of mantle cell lymphoma

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

Acute Myeloid Leukemia

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Targeting the JAK/STAT pathway in solid tumors

Selective JAK inhibitors in development for rheumatoid arthritis

Natural product and natural product derived drugs in clinical trials

Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor

Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes